Amorfix to present cancer therapeutic program at AACR 2013

TSX: AMF 
TORONTO, Jan. 24, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that 
the company has been selected to present an oral platform entitled 
"AMF-1c-120: an antibody specific for misfolded prion protein expressed on 
ovarian cancer cells", at the annual meeting of the American Association for 
Cancer Research (AACR) in Washington, DC on April 9, 2013. 
The Company will present the results of studies demonstrating the selective 
binding of its proprietary antibody, AMF-1c-120, to ovarian cancer cells, but 
not normal ovarian cells, as well as the killing of ovarian cancer cells with 
an antibody-toxin conjugate. These results validate the Company's ProMIS™ 
discovery technology as a valuable scientific platform enabling the 
development of novel, targeted therapeutic antibodies for the treatment of 
cancer and other diseases. 
Dr. Neil Cashman, Amorfix's Chief Scientific Officer said, "It is an honour to 
be one of the few participants selected for an oral presentation at this 
premier cancer research conference. We look forward to sharing our exciting 
results with the scientific community working to battle this common and 
terrible disease". 
The Company is developing AMF-1c-120 as a new therapeutic for the treatment of 
ovarian cancer and is in preclinical animal models of disease at present. 
The Company is also developing additional antibodies for the treatment of 
other types of cancers with their unique and proprietary ProMIS™ platform 
for identifying cancer specific targets that spare normal cells. 
About the ProMIS Discovery Technology and the Company's Prion Protein (PrP) 
Target
Amorfix's proprietary drug discovery technology, ProMIS™, is a computer 
based algorithm that predicts Disease Specific Epitopes (DSEs), those regions 
of proteins most likely to misfold in diseases. Misfolded proteins are found 
in numerous diseased cells, including various cancers and neurodegenerative 
diseases. The Company uses this technology to identify DSEs which are only 
expressed on tumor cells and not on normal cells as a way of developing 
antibodies that only bind to and kill tumor cells without affecting normal 
cells. Using this technology, Amorfix has the potential to create antibody 
therapeutics that are more efficacious and have a much better safety profile, 
with fewer side effects than current cancer therapeutics. 
About Ovarian Cancer
Ovarian cancer is the fifth most common cancer among women, and it causes more 
deaths than any other type of female reproductive cancer. Most deaths from 
ovarian cancer occur in women age 55 and older. Ovarian cancer is often not 
diagnosed until late-stage disease when the cancer has spread to other organs 
in the body, which contributes to the short survival time following diagnosis. 
Ovarian cancer is typically treated with surgery and chemotherapy. 
Chemotherapy is not very effective as a treatment and is associated with a 
number of potential dose-limiting side effects due to its non-specific killing 
of both tumour and normal cells. 
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated 
a human cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD) 
and mild cognitive impairment (MCI), and an ultrasensitive method for 
detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF 
and blood from animal models of AD. For more information about Amorfix, visit 
www.amorfix.com 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. This information release may contain certain 
forward-looking information. Such information involves known and unknown 
risks, uncertainties and other factors that may cause actual results, 
performance or achievements to be materially different from those implied by 
statements herein, and therefore these statements should not be read as 
guarantees of future performance or results. All forward-looking statements 
are based on the Company's current beliefs as well as assumptions made by and 
information currently available to it as well as other factors. Readers are 
cautioned not to place undue reliance on these forward-looking statements, 
which speak only as of the date of this press release. Due to risks and 
uncertainties, including the risks and uncertainties identified by the Company 
in its public securities filings, actual events may differ materially from 
current expectations. The Company disclaims any intention or obligation to 
update or revise any forward-looking statements, whether as a result of new 
information, future events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd.  
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 bob.gundel@amorfix.com  Janet 
Clennett Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 
847-6926 Fax: (416) 847-6899 janet.clennett@amorfix.com 
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2013/24/c8316.html 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
NI: MTC SHOW  
-0- Jan/24/2013 12:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.